High-dose vitamin B3 shows promise in glioblastoma trial
· Science
A small trial found that high-dose vitamin B3 (niacin) added to standard glioblastoma treatment led to 82% of patients remaining progression-free after six months. Researchers believe niacin may help revive immune cells suppressed by the cancer, but larger studies are needed to confirm.
Why it matters：If confirmed, high-dose vitamin B3 could become an inexpensive adjunct treatment for glioblastoma, affecting oncology research.
Key points
- High-dose vitamin B3 (niacin) was added to standard glioblastoma treatment.
- 82% of patients in the small trial remained progression-free after six months.
- Researchers believe niacin may revive immune cells suppressed by the cancer; larger studies are needed.
Sources (original reporting)
More stories from this day
- Major trial finds diet drinks as effective as water for weight loss
- FDA finds cyclospora at Mexican farm linked to lettuce outbreak
- New light-activated material produces hydrogen from water without metal catalyst
- Cutting emissions now may limit Antarctic ice loss, sea-level rise
- Nvidia and SoftBank close final $20B investment in OpenAI round
- FlyDubai co-pilot's axe attack ruled attempted terrorism